Advanced Biomed INC 8-K filings

Advanced Biomed Inc. has terminated its $25 million share purchase agreement with Helena Global Investment Opportunities I Ltd., effective July 21, 2026.

Advanced Biomed Inc. announced the results of its annual meeting of stockholders held on June 30, 2026, where all director nominees were elected and key proposals were approved.

Advanced Biomed Inc. has entered into a Share Purchase Agreement to sell its wholly-owned Taiwan subsidiary, which handles its biomedical R&D, for $490,000.

Advanced Biomed Inc. is transitioning from life sciences to artificial intelligence, appointing Xiaomin Chen as CEO following the acquisition of Acellent Technologies.

Advanced Biomed Inc. has entered into a material definitive agreement for a $600,000 unsecured loan with Jie Wang, to be used for operational purposes.

Advanced Biomed Inc. has entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, an AI-powered financial verification and audit solutions provider.

Advanced Biomed announced the resignation of CTO and director Steven I-Fang Cheng and appointed CFO Mingze Yin to the board, effective March 25, 2026.

Advanced Biomed Inc. successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split, avoiding delisting.

Advanced Biomed Inc. completed a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Advanced Biomed Inc. issued 1.65 million shares as a commitment fee for a previously announced $25 million equity line of credit.

Advanced Biomed Inc. has completed a private placement of 4 million common shares to investors, raising $248,000 for general corporate purposes.

Advanced Biomed Inc. entered a supplemental agreement to ensure its former subsidiary, Advanced Biomed (HK) Limited, repays a $6.9 million debt within one year.

Advanced Biomed Inc. received a delisting notice from Nasdaq for failing to meet the minimum bid price requirement but has appealed the decision and plans a reverse stock split.

Advanced Biomed Inc. has sold its Hong Kong subsidiary, including all associated intellectual property, for $23,000 to streamline operations and centralize clinical trials in Taiwan.

Advanced Biomed Inc. announced the launch of its A+PerfusC Integrated Perfusion 3D Cell Culture Platform for precision medicine and drug discovery.

Advanced Biomed Inc. has received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Advanced Biomed Inc. has entered into a purchase agreement with Helena Global Investment Opportunities I Ltd. for an equity line of credit of up to $25 million, providing flexible access to capital for general corporate purposes.

Advanced Biomed Inc. has announced the resignation of Dr. Hung To Pau from its Board of Directors and the immediate appointment of Mr. Steven I-Fang Cheng as a new board member.

Advanced Biomed Inc. details the terms of its IPO, including the issuance of warrants to the underwriter, Craft Capital Management LLC.